Profile: Lupin siblings on dinner table chats and not emulating Teva

This C-suite interview was quite different. It was one filled with plenty of sis-bro banter and peals of laughter amid all the serious talk on where India's third largest pharmaceutical company by sales sees itself by around 2020 and how it does not intend to emulate Teva, whose business model some peers look up to.